Our company is a large-scale comprehensive group owning a public stock company (Huadong Medicine Co Ltd), several joint ventures (Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd, Hangzhou MSD Pharmaceutical Co Ltd, Hangzhou Jiuyuan Gene Engineering Co Ltd, Zhejiang Huayi Pharmaceutical Co Ltd and Zhejiang ESTEVE-HUAYI Pharmaceutical Co Ltd) and series of share-holder pharmaceutical and chemical companies.

We are manufacturers of Dosages, APIs and intermediates by fermentation, synthesis and biotechnology, especially in the area of immunosuppressant and anti-diobetic agents. Our main products include: Acarbose, Cyclosporine, Febuxostat, Mycophenolate Mofetil, Orlistat, Sirolimus, Tacrolimus, Everolimus, etc. and series of finishend dosage, including tablets, capsules, injection, oral solution.

Related Categories

Sales Markets

Middle East Region (e.g. UAE); Oceania; North America (USA, Canada); Africa; Central America (e.g. Mexico); East Asia (e.g. China, Japan, Korea); Europe - EU countries; Europe - non EU (e.g. UK, Russia, ex-CIS countries); South America (e.g. Brazil, Colombia); South Asia (e.g. India, Pakistan, Sri Lanka); South East Asia (e.g. Thailand, Philippines, Singapore)